文献速递眼底病与葡萄膜炎

从数据到部署:眼科影像协作社区关于年龄相关性黄斑变性人工智能的路线图

From Data to Deployment: The Collaborative Community on Ophthalmic Imaging Roadmap for Artificial Intelligence in Age-Related Macular Degeneration.
PubMed 文献 · Ophthalmology · 2022-01-10

本文由眼科影像协作社区人工智能在年龄相关性黄斑变性(AMD)工作组撰写,于2020年9月7日召开首次会议并综述相关医学文献至2021年12月达成共识。文章阐述了AMD人工智能的现状、数据、标准、成就与挑战,指出目前尚无美国食品药品监督管理局(FDA)批准的AMD人工智能设备,并提出了未来目标。

要点

  • 现有AMD人工智能开发基础设施包括多个大型彩色眼底照相和OCT图像标记数据集。
  • 图像数据常缺乏开发可靠、有效且可泛化模型所需的元数据。
  • 尽管存在数据隐私、计算资源和机器学习知识等挑战,研究者已产出有前景的AMD人工智能模型。

核心结论

  • 交付FDA授权的AMD人工智能临床设备涉及诸多考量,包括确定合适临床应用、获取和开发大型高质量数据集、开发人工智能架构、训练和验证模型以及模型输出与临床终端用户的功能交互。
  • 迄今为止的研究努力代表了最终将使提供者、卫生系统和患者受益的医疗设备的起点。

研究设计与样本

  • 眼科影像协作社区人工智能在AMD工作组于2020年9月7日召开首次会议讨论该主题,随后对相关医学文献进行了全面综述,并通过会议和讨论至2021年12月综合信息并达成共识。

主要发现

  • 现有AMD人工智能开发基础设施包括多个大型彩色眼底照相和OCT图像标记数据集。
  • 图像数据常不包含开发可靠、有效和可泛化模型所需的元数据。
  • 由于数据隐私和安全限制,AMD模型开发的数据共享变得困难,尽管潜在解决方案正在研究中。
  • 计算资源对当前应用可能足够,但在许多临床眼科环境中机器学习开发知识可能稀缺。
  • 尽管存在这些挑战,研究人员已为AMD的筛查、诊断、预测和监测产出了有前景的人工智能模型。

关键数值与推荐

  • 未来目标包括定义基准以促进监管授权和随后的临床环境泛化。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Health care systems worldwide are challenged to provide adequate care for the 200 million individuals with age-related macular degeneration (AMD). Artificial intelligence (AI) has the potential to make a significant, positive impact on the diagnosis and management of patients with AMD; however, the development of effective AI devices for clinical care faces numerous considerations and challenges, a fact evidenced by a current absence of Food and Drug Administration (FDA)-approved AI devices for AMD. PURPOSE: To delineate the state of AI for AMD, including current data, standards, achievements, and challenges. METHODS: Members of the Collaborative Community on Ophthalmic Imaging Working Group for AI in AMD attended an inaugural meeting on September 7, 2020, to discuss the topic. Subsequently, they undertook a comprehensive review of the medical literature relevant to the topic. Members engaged in meetings and discussion through December 2021 to synthesize the information and arrive at a consensus. RESULTS: Existing infrastructure for robust AI development for AMD includes several large, labeled data sets of color fundus photography and OCT images; however, image data often do not contain the metadata necessary for the development of reliable, valid, and generalizable models. Data sharing for AMD model development is made difficult by restrictions on data privacy and security, although potential solutions are under investigation. Computing resources may be adequate for current applications, but knowledge of machine learning development may be scarce in many clinical ophthalmology settings. Despite these challenges, researchers have produced promising AI models for AMD for screening, diagnosis, prediction, and monitoring. Future goals include defining benchmarks to facilitate regulatory authorization and subsequent clinical setting generalization. CONCLUSIONS: Delivering an FDA-authorized, AI-based device for clinical care in AMD involves numerous considerations, including the identification of an appropriate clinical application; acquisition and development of a large, high-quality data set; development of the AI architecture; training and validation of the model; and functional interactions between the model output and clinical end user. The research efforts undertaken to date represent starting points for the medical devices that eventually will benefit providers, health care systems, and patients.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Dow ER, Keenan TDL, Lad EM, et al. From Data to Deployment: The Collaborative Community on Ophthalmic Imaging Roadmap for Artificial Intelligence in Age-Related Macular Degeneration. Ophthalmology. 2022. PMID: 35016892. doi:10.1016/j.ophtha.2022.01.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。